BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients |
| January 28, 2021 | January 2021 Bond Updates |
|
LUND, Sweden, Jan. 28, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces positive interim results from... |
| View more at: https://www.prnewswire.com:443/news-releases/bioinvent-phase-iiia-data-suggest-bi-1206-restores-activity-of-rituximab-in-relapsed-non-hodgkins-lymphoma-patients-301216922.html |
| Related News |